drugset / Trial / NCT06483100
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Phase 2
Recruiting
65 enrolled
Washington University School of Medicine
National Comprehensive Cancer Network · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.
Timeline
- Start
- 2024-12-20
- Primary completion
- 2031-12-31
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elranatamab | Monoclonal antibody | 76 mg | Subcutaneous |